Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

Javle M1, Borad MJ2, Azad NS3, Kurzrock R4, Abou-Alfa GK5, George B6, Hainsworth J7, Meric-Bernstam F8, Swanton C9, Sweeney CJ10, Friedman CF5, Bose R11, Spigel DR7, Wang Y12, Levy J12, Schulze K12, Cuchelkar V12, Patel A12, Burris H7
  1. Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mjavle@mdanderson.org.
  2. Mayo Clinic, Scottsdale, AZ, USA.
  3. Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  4. Moores Cancer Center, University of California San Diego, San Diego, CA, USA.
  5. Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College at Cornell University, New York, NY, USA.
  6. Medical College of Wisconsin, Milwaukee, WI, USA.
  7. Sarah Cannon Research Institute, Nashville, TN, USA; Tennessee Oncology, Nashville, TN, USA.
  8. Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  9. Francis Crick Institute, London, UK; UCL Hospitals, London, UK.
  10. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  11. Washington University School of Medicine, St Louis, MO, USA.
  12. Genentech, South San Francisco, CA, USA.